Seres Therapeutics, Inc.
MCRBNasdaqCIK 1609809HealthcareFiscal year ends Dec 31
Reports and events: 186 filings
Newest first, by EDGAR acceptance time (Eastern). Each filing’s page lists its documents on sec.gov and, for 10-K and 10-Q reports, the extracted sections.
What the forms are: 10-K, 10-Q, 8-K, Form 4, DEF 14A, Schedule 13D, Schedule 13G, amendments, accession numbers.
| Filed | Form | What it is | Accession number |
|---|---|---|---|
| 2026-08-0510:30 ET | 10-Q | Quarterly reportPeriod 2026-06-30 | 0001193125-26-334174 |
| 2026-08-0507:05 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001193125-26-333820 |
| 2026-08-0416:03 ET | 8-K | 1.01 Entry into a material agreement; 1.02 Termination of a material agreement; 9.01 Financial statements and exhibits | 0001193125-26-332742 |
| 2026-07-0816:05 ET | 8-K | 5.02 Departure or appointment of officers or directors; 5.07 Shareholder vote results; 9.01 Financial statements and exhibits | 0001193125-26-298525 |
| 2026-07-0808:00 ET | 8-K | 7.01 Regulation FD disclosure; 8.01 Other events; 9.01 Financial statements and exhibits | 0001193125-26-298005 |
| 2026-06-0507:05 ET | 8-K | 1.01 Entry into a material agreement; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001193125-26-258366 |
| 2026-06-0116:30 ET | 8-K | 5.02 Departure or appointment of officers or directors | 0001193125-26-251548 |
| 2026-05-0510:30 ET | 10-Q | Quarterly reportPeriod 2026-03-31 | 0001193125-26-205434 |
| 2026-05-0507:05 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001193125-26-205009 |
| 2026-04-2716:05 ET | DEF 14A | Proxy statementPeriod 2026-06-09 | 0001193125-26-182036 |
| 2026-03-1616:42 ET | 8-K | 8.01 Other events | 0001193125-26-108482 |
| 2026-03-1210:00 ET | 10-K | Annual reportPeriod 2025-12-31 | 0001193125-26-103276 |
| 2026-03-1207:05 ET | 8-K | 2.02 Results of operations; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001193125-26-103034 |
| 2026-03-0216:05 ET | 8-K | 5.02 Departure or appointment of officers or directors; 9.01 Financial statements and exhibits | 0001193125-26-085368 |
| 2025-11-0510:00 ET | 10-Q | Quarterly reportPeriod 2025-09-30 | 0001193125-25-266011 |
| 2025-11-0507:05 ET | 8-K | 2.02 Results of operations; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001193125-25-265708 |
| 2025-10-0316:06 ET | 8-K | 8.01 Other events | 0001193125-25-230118 |
| 2025-08-0610:00 ET | 10-Q | Quarterly reportPeriod 2025-06-30 | 0000950170-25-103611 |
| 2025-08-0607:05 ET | 8-K | 2.02 Results of operations; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001193125-25-173985 |
| 2025-07-2216:10 ET | 8-K | 5.02 Departure or appointment of officers or directors | 0001193125-25-162552 |
| 2025-05-0710:00 ET | 10-Q | Quarterly reportPeriod 2025-03-31 | 0000950170-25-065173 |
| 2025-05-0707:05 ET | 8-K | 2.02 Results of operations; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001193125-25-114430 |
| 2025-04-2216:05 ET | 8-K | 5.03 Amendment to articles or bylaws; 9.01 Financial statements and exhibits | 0001193125-25-089189 |
| 2025-04-1416:13 ET | 8-K | 5.02 Departure or appointment of officers or directors; 5.07 Shareholder vote results; 8.01 Other events; 9.01 Financial statements and exhibits | 0001193125-25-080185 |
| 2025-03-1311:43 ET | DEF 14A | Proxy statementPeriod 2025-03-13 | 0000950170-25-038441 |
| 2025-03-1311:24 ET | 10-K | Annual reportPeriod 2024-12-31 | 0000950170-25-038427 |
| 2025-03-1307:07 ET | 8-K | 2.02 Results of operations; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001193125-25-053473 |
| 2025-02-2716:15 ET | 8-K | 5.02 Departure or appointment of officers or directors | 0001193125-25-039256 |
| 2025-02-0608:00 ET | 8-K | 5.02 Departure or appointment of officers or directors | 0001193125-25-021345 |
| 2025-01-1308:06 ET | 8-K | 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001193125-25-005011 |
| 2025-01-1007:00 ET | 8-K | 2.02 Results of operations; 8.01 Other events; 9.01 Financial statements and exhibits | 0001193125-25-004062 |
| 2024-11-1310:30 ET | 10-Q | Quarterly reportPeriod 2024-09-30 | 0000950170-24-126018 |
| 2024-11-1308:05 ET | 8-K | 2.02 Results of operations; 3.01 Delisting notice; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001193125-24-256654 |
| 2024-10-0208:15 ET | SC 13D/A | Ownership report, active investor, amended | 0001193125-24-230718 |
| 2024-10-0116:05 ET | 8-K | 1.01 Entry into a material agreement; 1.02 Termination of a material agreement; 2.01 Completion of an acquisition or disposition; 3.02 Unregistered sale of equity; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001193125-24-230144 |
| 2024-09-2616:13 ET | 8-K | 5.07 Shareholder vote results; 9.01 Financial statements and exhibits | 0001193125-24-226929 |
| 2024-09-1207:05 ET | 8-K | 7.01 Regulation FD disclosure; 8.01 Other events; 9.01 Financial statements and exhibits | 0001193125-24-217627 |
| 2024-08-1506:05 ET | 8-K | 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001140361-24-037388 |
| 2024-08-1310:38 ET | 10-Q | Quarterly reportPeriod 2024-06-30 | 0000950170-24-095821 |
| 2024-08-1307:05 ET | 8-K | 2.02 Results of operations; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001193125-24-199382 |
| 2024-08-0617:27 ET | 8-K | 1.01 Entry into a material agreement; 1.02 Termination of a material agreement; 3.02 Unregistered sale of equity; 9.01 Financial statements and exhibits | 0001140361-24-035951 |
| 2024-08-0607:39 ET | 8-K | 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001140361-24-035799 |
| 2024-05-0810:00 ET | 10-Q | Quarterly reportPeriod 2024-03-31 | 0000950170-24-055159 |
| 2024-05-0807:05 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001193125-24-133766 |
| 2024-05-0717:18 ET | 8-K | 2.04 Item not in the standard list | 0001193125-24-133298 |
| 2024-04-2307:00 ET | 8-K | 3.01 Delisting notice | 0001193125-24-105862 |
| 2024-04-0816:30 ET | 8-K | 5.03 Amendment to articles or bylaws; 5.07 Shareholder vote results; 9.01 Financial statements and exhibits | 0001193125-24-089654 |
| 2024-03-0510:18 ET | DEF 14A | Proxy statementPeriod 2024-03-05 | 0000950170-24-025482 |
| 2024-03-0510:01 ET | 10-K | Annual reportPeriod 2023-12-31 | 0000950170-24-025464 |
| 2024-03-0507:05 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001193125-24-058584 |
Source: SEC EDGAR, the company’s filing index. Last ingested by Listed: Oct 26, 2026, 16:31 ET. Listed shows no prices and gives no investment advice.